Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 501 to 510 of 2440 total matches.
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019 (Issue 1582)
-related conditions. Vaccines recommended
for travelers are reviewed in a separate issue.1
TRAVELERS ...
Patients who receive pretravel advice can reduce their
risk for many travel-related conditions. Vaccines recommended
for travelers are reviewed in a separate issue.
Expanded Table: Antibiotics for Travelers' Diarrhea (online only)
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019 (Issue 1582)
▶ Not recommended for use in children
1.60
34.40
Levofloxacin3 – generic
Levaquin (Janssen)
200, 500, 750 mg ...
View the Expanded Table: Antibiotics for Travelers' Diarrhea
Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (online only)
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019 (Issue 1582)
▶ Recommended for prevention of AMS in
adults and children
$3.00
Dexamethasone – generic 0.5, 0.75, 1, 1.5, 2 ...
View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness
Qmiiz ODT - An Orally Disintegrating Meloxicam Tablet
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
. Vivlodex, a low-dose
capsule formulation of meloxicam, is FDA-approved
only for management of OA pain.1 ...
The FDA has approved Qmiiz ODT (TerSera), an orally
disintegrating tablet formulation of the prescription
NSAID meloxicam. Qmiiz ODT, like conventional oral
meloxicam tablets (Mobic, and generics), is indicated
for relief of the symptoms of osteoarthritis (OA) and
rheumatoid arthritis (RA) in adults and of juvenile RA
in children who weigh ≥60 kg. Vivlodex, a low-dose
capsule formulation of meloxicam, is FDA-approved
only for management of OA pain.
Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
see' mee
SEVERE HYPOGLYCEMIA – Hypoglycemia is
classified as level 1 (blood glucose ≥54 and ...
The FDA has approved glucagon nasal powder
(Baqsimi – Lilly) for treatment of severe hypoglycemia
in patients ≥4 years old with diabetes. Baqsimi is the
first noninjectable glucagon formulation to become
available in the US. Injectable glucagon emergency kits
(GlucaGen Hypokit, and generic) have been available
for years, but they require reconstitution of the
lyophilized powder by the caregiver immediately before
injection. An injectable glucagon formulation that does
not require reconstitution was recently approved by the
FDA (Gvoke) and is expected to become available...
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
to be approved in the
US; retapamulin (Altabax), a 1% topical ointment for
treatment of impetigo, was approved ...
Lefamulin (Xenleta – Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the first
systemic pleuromutilin antibiotic to be approved in the
US; retapamulin (Altabax), a 1% topical ointment for
treatment of impetigo, was approved in 2007.
Duaklir Pressair: Another LAMA/LABA Inhaler for COPD
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
therapy, addition of an inhaled corticosteroid
is recommended.1,2
CLINICAL STUDIES — In two 24-week ...
The FDA has approved Duaklir Pressair (Circassia), a
fixed-dose combination of the long-acting muscarinic
antagonist (LAMA) aclidinium bromide and the longacting
beta2-adrenergic agonist (LABA) formoterol
fumarate, for maintenance treatment of chronic
obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be
approved in the US for this indication.
In Brief: Ezallor Sprinkle - A New Formulation of Rosuvastatin
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
tablets (Crestor, and generics)
have been available since 2003.1,2
Table 1: Rosuvastatin Products
Drug ...
The lipid-lowering drug rosuvastatin is now available in a sprinkle capsule formulation (Ezallor Sprinkle – Sun Pharma). Rosuvastatin tablets (Crestor, and generics) have been available since 2003.1,2The new formulation is being marketed specifically for residents of long-term care facilities who have difficulty swallowing. Ezallor Sprinkle capsules can be swallowed whole or opened and their contents sprinkled over applesauce or mixed with water for administration via nasogastric tube.For those long-term care residents who still have a reasonable indication for a statin but have difficulty...
Expanded Table: Statins (online only)
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
The Medical Letter ® Vol. 61 (1581) September 23, 2019
Table 1. Statins
Average LDL-C
Drug Some ...
View the Expanded Table: Statins
Solriamfetol (Sunosi) for Excessive Daytime Sleepiness
The Medical Letter on Drugs and Therapeutics • Aug 26, 2019 (Issue 1579)
, and insomnia.
▶ A schedule IV controlled substance.
▶ A 30-day supply costs $660.00.
Table 1. Pharmacology ...
The FDA has approved solriamfetol (Sunosi – Jazz),
a dopamine and norepinephrine reuptake inhibitor
(DNRI), to improve wakefulness in adults with excessive
daytime sleepiness (EDS) associated with narcolepsy
or obstructive sleep apnea (OSA). Pitolisant (Wakix),
an H3-receptor antagonist/inverse agonist recently
approved by the FDA for treatment of excessive
daytime sleepiness in patients with narcolepsy, will be
reviewed in a future issue.